NCT05684172 is a Phase 2, PHASE3 clinical trial of Tenecteplase in Acute Ischemic Stroke, sponsored by The First Affiliated Hospital of University of Science and Technology of China.

What drugs are being tested in NCT05684172?

Interventions in NCT05684172: Tenecteplase, endovascular thrombectomy alone.

What condition does NCT05684172 study?

NCT05684172 studies Acute Ischemic Stroke, Intracranial Artery Occlusion, Endovascular Thrombectomy.

Is NCT05684172 still recruiting?

NCT05684172 is currently completed. Last updated 11 April 2024.

Last reviewed 2024-04-11 · How we verify

NCT05684172

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intra-arterial TNK Following Endovascular Thrombectomy in Patients With Large Vessel Occlusion of Posterior Circulation

Completed Phase 2, PHASE3 Last updated 11 April 2024

What this trial tests

Phase 2, PHASE3 trial testing Tenecteplase in Acute Ischemic Stroke in 208 participants. Completed in 24 November 2023.

Timeline

24 January 2023

Primary endpoint
24 August 2023

24 November 2023

Quick facts

Lead sponsor	The First Affiliated Hospital of University of Science and Technology of China
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	208
Start date	24 January 2023
Primary completion	24 August 2023
Estimated completion	24 November 2023
Sites	1 location across China

Drugs / interventions tested

Tenecteplase (TENECTEPLASE) — full drug profile →
endovascular thrombectomy alone

Conditions studied

Acute Ischemic Stroke — all drugs for Acute Ischemic Stroke →
Intracranial Artery Occlusion — all drugs for Intracranial Artery Occlusion →
Endovascular Thrombectomy — all drugs for Endovascular Thrombectomy →

Sponsor

The First Affiliated Hospital of University of Science and Technology of China

Who can join

18 and older, any sex, with Acute Ischemic Stroke or Intracranial Artery Occlusion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Rationale: Recently, one prospective multicenter RCT reported a potential beneficial effect of intra-arterial alteplase following successful endovascular thrombectomy (EVT) in patients with an acute intracranial large vessel occlusion. In 2018, another prospective multicenter RCT supported the superiority of tenecteplase over alteplase in ischemic stroke patients with large vessel occlusion. Objective: To assess the effect of EVT in addition to intra-arterial tenecteplase compared to EVT alone, in patients with large vessel occlusion of posterior circulation, on functional and safety outcomes. Study design: This is a parallel group, randomized clinical trial of EVT with IA-TNK versus EVT. The trial has observer blind assessment of the primary outcome and of neuro-imaging at baseline and follow-up. Study population: Patients with acute intracranial large vessel occlusion of posterior circulation and an eTICI 2b-3 after EVT. Main study parameters/outcomes: The primary effect parameter will be excellent functional status at day 90 defined as a modified Rankin Score (mRS) of 0-1. The estimate will be adjusted for the known prognostic variables age, pre-stroke mRS, time from onset to randomization, stroke severity (NIHSS) and collaterals and adjusted and unadjusted estimates with corresponding 95% confidence intervals will be reported.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Comprehensive Review of Tenecteplase for Thrombolysis in Acute Ischemic Stroke.
Wang L, Hao M, Wu N, Wu S, et al · · 2024 · cited 48× · PMID 38686848 · DOI 10.1161/jaha.123.031692
Intra-arterial tenecteplase after successful endovascular recanalisation in patients with acute posterior circulation arterial occlusion (ATTENTION-IA): multicentre randomised controlled trial.
Hu W, Tao C, Wang L, Chen Z, et al · · 2025 · cited 35× · PMID 39809509 · DOI 10.1136/bmj-2024-080489
Intra-arterial alteplase for acute ischaemic stroke after mechanical thrombectomy (PEARL): rationale and design of a multicentre, prospective, open-label, blinded-endpoint, randomised controlled trial.
Yang X, He X, Pan D, Xu Y, et al · · 2024 · cited 16× · PMID 39500603 · DOI 10.1136/bmjopen-2024-091059
Intra-arterial tenecteplase following endovascular therapy in patients with acute posterior circulation arterial occlusion: study protocol and rationale.
Tao C, Li R, Sun J, Zhu Y, et al · · 2024 · cited 15× · PMID 38124230 · DOI 10.1136/jnis-2023-021076
Natural Evolution of Incomplete Reperfusion in Patients Following Endovascular Therapy After Ischemic Stroke.
Mujanovic A, Windecker D, Cimflova P, Meinel TR, et al · · 2025 · cited 7× · PMID 39567366 · DOI 10.1161/strokeaha.124.049641
Adjunctive Thrombolytics After Successful Endovascular Reperfusion: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Doheim MF, Mohammaden MH, Jumah A, Yang Q, et al · · 2025 · cited 6× · PMID 40799167 · DOI 10.1002/ana.70021
Noncontrast CT vs CT Perfusion Imaging in Patients With Basilar Artery Occlusion: Analysis of the ATTENTION and ATTENTION IA Trials.
Hu W, Nguyen TN, Qureshi M, Chen Z, et al · · 2025 · cited 2× · PMID 40674670 · DOI 10.1212/wnl.0000000000213911
A Review on Adjunctive Therapies for Endovascular Treatment in Acute Ischemic Stroke.
Goyal M, Rinkel LA, Ospel JM. · · 2023 · cited 2× · PMID 38025256 · DOI 10.5797/jnet.ra.2023-0035

Verify or expand the search:

Other trials of Tenecteplase

Trials testing the same drug.

NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
NCT07361302 — A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Pe · Phase 3 · recruiting
NCT06658197 — Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke · Phase 3 · recruiting
NCT06621121 — A Real-world Study of Tenecteplase Versus Alteplase for Thrombolysis in Patients Within 4.5 H of Onset of Ischemic Strok · recruiting

Other recruiting trials for Acute Ischemic Stroke

Currently open trials in the same condition.

NCT07115940 — Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours · NA · recruiting
NCT07404852 — Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemi · NA · recruiting
NCT07361302 — A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Pe · Phase 3 · recruiting
NCT07436156 — SUMMIT RISE Study of Acute Ischemic Stroke Patients · Phase 4 · recruiting
NCT07203625 — Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours · Phase 4 · recruiting

Other The First Affiliated Hospital of University of Science and Technology of China trials

Trials by the same sponsor.

NCT07449910 — Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A · Phase 2, PHASE3 · not yet recruiting
NCT07168278 — Tenecteplase vs Medical Management in 4.5-24h LVO no Access to EVT · Phase 3 · not yet recruiting
NCT07214142 — Total Neoadjuvant Therapy With PD-1 for Locally Advcancer Rectal Cancer · Phase 2 · not yet recruiting
NCT07094763 — Efficacy and Safety of Tenecteplase Intravenous Thrombolysis in Acute Posterior Circulation Ischemic Stroke Within 4.5-2 · NA · not yet recruiting
NCT06559475 — A Multicenter, Randomized Controlled Clinical Investigation to Evaluate the Safety and Effectiveness of the Super-Bore 8 · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05684172 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of University of Science and Technology of China
Last refreshed: 11 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05684172.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing